Genome-scale clustered regularly interspaced short palindromic repeats screen identifies nucleotide metabolism as an actionable therapeutic vulnerability in diffuse large B-cell lymphoma

by Nicholas Davies, Tegan Francis, Ceri Oldreive, Maria Azam, Jordan Wilson, Philip J. Byrd, Megan Burley, Archana Sharma-Oates, Peter Keane, Sae Alatawi, Martin R. Higgs, Zbigniew Rudzki, Maha Ibrahim, Tracey Perry, Angelo Agathanggelou, Anne-Marie Hewitt, Edward Smith, Constanze Bonifer, Mark O’Connor, Josep V. Forment, Paul G. Murray, Eanna Fennell, Gemma Kelly, Catherine Chang, Grant S. Stewart, Tanja Stankovic, Marwan Kwok, and Alexander Malcolm Taylor

Received: October 4, 2023.
Accepted: May 24, 2024.

Citation: Nicholas Davies, Tegan Francis, Ceri Oldreive, Maria Azam, Jordan Wilson, Philip J. Byrd, Megan Burley, Archana Sharma-Oates, Peter Keane, Sae Alatawi, Martin R. Higgs, Zbigniew Rudzki, Maha Ibrahim, Tracey Perry, Angelo Agathanggelou, Anne-Marie Hewitt, Edward Smith, Constanze Bonifer, Mark O’Connor, Josep V. Forment, Paul G. Murray, Eanna Fennell, Gemma Kelly, Catherine Chang, Grant S. Stewart, Tanja Stankovic, Marwan Kwok, and Alexander Malcolm Taylor. Genome-scale clustered regularly interspaced short palindromic repeats screen identifies nucleotide metabolism as an actionable therapeutic vulnerability in diffuse large B-cell lymphoma.

Publisher’s Disclaimer.
E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors’ final approval; the final version of the manuscript will then appear in a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.
Genome-scale clustered regularly interspaced short palindromic repeats screen identifies nucleotide metabolism as an actionable therapeutic vulnerability in diffuse large B-cell lymphoma

*Nicholas Davies1, *Tegan Francis1, Ceri Oldrieve1, Maria Azam1, Jordan Wilson1, Philip J. Byrd1, Megan Burley1, Archana Sharma-Oates2, Peter Keane1, Sael Alatawi1,3, Martin R. Higgs1, Zbigniew Rudzki4, Maha Ibrahim1,5, Tracey Perry1, Angelo Agathaggelou1, Anne-Marie Hewitt1, Edward Smith1, Constanze Bonifer1, Mark O’Connor6, Josep V. Forment6, Paul G. Murray7, Eanna Fennell7, Gemma Kelly8, Catherine Chang8, Grant S. Stewart1, Tatjana Stankovic1, Marwan Kwok1,9, and Alexander Malcolm Taylor1

1Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK
2School of Biosciences, University of Birmingham, Birmingham, UK
3Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia
4Department of Histopathology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
5South Egypt Cancer Institute, Assiut University, Egypt
6Bioscience Oncology R&D, AstraZeneca, Cambridge, UK
7School of Medicine, Bernal Institute, Health Research Institute & LDCRC, University of Limerick, Limerick, Ireland
8Blood Cells and Blood Cancer Division, The Walter and Eliza Hall Institute of Medical Research, Victoria, Australia
9Centre for Clinical Haematology, Queen Elizabeth Hospital Birmingham, Birmingham, UK

Running heads: Targeting nucleotide metabolism in DLBCL

Corresponding authors:

1. Alexander Malcolm Taylor, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK, B15 2TT; e-mail: a.m.r.taylor@bham.ac.uk; Tel: +44 121 4144488

2. Marwan Kwok, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK, B15 2TT, e-mail: m.kwok@bham.ac.uk; Tel: +44 121 4144496

3. Tatjana Stankovic, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK, B15 2TT; e-mail: t.stankovic@bham.ac.uk; Tel: +44 121 4144496
Authors’ contributions: ND and TF contributed equally as co-first authors’. ND, TF, CO, MA, JW, PJB, MB, MH, RZ, MI, TP, AA, A-MH, ES, GK and CC performed experiments; ND, TF, CO, AS-O, PK, SA, MH, CB, PGM, EF and MK analyzed results; ND, TF, PJB, MO’C, JVF, GSS, TS and AMT designed the research; ND, TF, CO, TS, MK, and AMT wrote the paper.


Acknowledgments: We thank Mike Griffiths (West Midlands Regional Genetics Laboratory) and Robert Hollows (Institute of Cancer and Genomic Sciences) for their expertise with data analysis; Paloma Garcia (Institute of Cancer and Genomic Sciences), Rachel Bayley (Institute of Cancer and Genomic Sciences) and Clare Shannon-Lowe (Institute of Immunology and Immunotherapy) for experimental assistance; and the University of Birmingham Genomics Sequencing and Flow Cytometry Services for analytical help.

Funding: This work was supported by grants from CRUK (Ref: C20807/A2864 and C17183/A23303), Bloodwise UK (Programme grant 11045) and Action for A-T (Ref: 17-1192). C.B. was supported by grants from MRC and BCUK. P.M. was also supported in part by a European Regional Development Fund Project (ENOCHE: CZ.02.1.01/0.0/0.0/16_019/0000868). M.K. is a Cancer Research UK Clinician Scientist.

Competing Interests: MO’C and JVF are full-time employees and shareholders at AstraZeneca. The other authors declare no competing interests.
Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common malignancy that develops in patients with ataxia-telangiectasia, a cancer-predisposing inherited syndrome characterized by inactivating germline ATM mutations. ATM is also frequently mutated in sporadic DLBCL. To investigate lymphomagenic mechanisms and lymphoma-specific dependencies underlying defective ATM, we applied ribonucleic acid (RNA)-seq and genome-scale loss-of-function clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 screens to systematically interrogate B-cell lymphomas arising in a novel murine model (Atm<sup>−/−</sup> nu<sup>−/−</sup>) with constitutional Atm loss, thymic aplasia but residual T-cell populations. Atm<sup>−/−</sup> nu<sup>−/−</sup> lymphomas, which phenotypically resemble either activated B-cell-like or germinal center B-cell-like DLBCL, harbor a complex karyotype, and are characterized by MYC pathway activation. In Atm<sup>−/−</sup> nu<sup>−/−</sup> lymphomas, we discovered nucleotide biosynthesis as a MYC-dependent cellular vulnerability that can be targeted through the synergistic nucleotide-depleting actions of mycophenolate mofetil (MMF) and the WEE1 inhibitor, adavosertib (AZD1775). The latter is mediated through a synthetically lethal interaction between RRM2 suppression and MYC dysregulation that results in replication stress overload in Atm<sup>−/−</sup> nu<sup>−/−</sup> lymphoma cells. Validation in cell line models of human DLBCL confirmed the broad applicability of nucleotide depletion as a therapeutic strategy for MYC-driven DLBCL independent of ATM mutation status. Our findings extend current understanding of lymphomagenic mechanisms underpinning ATM loss and highlight nucleotide metabolism as a targetable therapeutic vulnerability in MYC-driven DLBCL.
Introduction

Dysregulation of the MYC proto-oncogene represents a fundamental mechanism underpinning pathogenesis in high-grade B-cell non-Hodgkin lymphoma (B-NHL). In diffuse large B-cell lymphoma (DLBCL), the most common form of high-grade B-NHL, MYC overexpression and chromosomal translocations, present in up to 40% and 20% of DLBCL respectively, confer inferior outcomes with standard rituximab-based chemoimmunotherapy. Moreover, concurrent overexpression of MYC and BCL-2 defines double-expressor DLBCL, while translocations of MYC with BCL2 and/or BCL6 characterize double/triple-hit lymphoma, both associated with dismal prognosis and poor response to standard chemoimmunotherapeutic approaches.

In addition to MYC disruption, recent next-generation sequencing efforts have revealed numerous other genomic events, unravelling a hitherto unrecognized level of genetic heterogeneity in DLBCL and other high-grade B-NHL. Furthermore, besides acquired somatic alterations that fuel clonal evolution, there is increasing recognition of germline genetic alterations as important predisposing factors for B-cell lymphomagenesis. Understanding the therapeutic vulnerability associated with these genetic alterations is essential for devising novel therapeutic strategies with potential to improve clinical outcome. In this regard, the tumor suppressor gene ataxia-telangiectasia mutated (ATM) is recurrently mutated in 8%-21% of sporadic DLBCL. Moreover, high-grade B-NHL, particularly DLBCL, is the most frequent cancer type seen in individuals with ataxia-telangiectasia (AT), an inherited cancer predisposition syndrome caused by biallelic inactivating germline ATM mutations. ATM plays a critical role in the maintenance of genome integrity through mediating deoxyribonucleic acid (DNA) repair, cell cycle arrest and/or apoptosis in response to DNA double-strand breaks. Beyond the DNA damage response, ATM participates in multifaceted cellular processes including regulation of chromatin remodeling, oxidative stress response, mitochondrial metabolism and autophagy. Despite in vivo evidence substantiating the role of ATM loss as a driver of DLBCL, its pathological consequence has not been fully elucidated. Moreover, little is known about the resultant cellular vulnerabilities that could be exploited for therapeutic targeting.

To address this issue, we combined ribonucleic acid (RNA)-seq and genome-scale clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 screens to systematically interrogate pathogenic mechanisms and cellular dependencies within a novel murine model of DLBCL harboring constitutional Atm loss. We uncovered distinct transcriptional alterations associated with Atm loss that result in MYC activation and identified nucleotide biosynthesis
among the actionable dependencies. We further demonstrated that nucleotide depletion induces a replication stress overload with resultant lethal effect that is dependent upon endogenous MYC overexpression in human DLBCL cells. Our findings thus unravel a novel mechanism underlying MYC dysregulation in ATM-defective DLBCL, providing a therapeutic approach for MYC-driven DLBCL and potentially other high-grade B-NHL that exploits nucleotide biosynthesis as a liability conferred by MYC dysregulation.

**Methods**

Details of assays performed according to established protocols are shown in the Online Supplementary Methods.

**Generation of Atm<sup>-/-</sup> nu<sup>-/-</sup> mice**

Animal studies were approved by the institutional ethics committee (AWERB) and conducted in accordance with UK Home Office regulations. The first mating of Atm heterozygote females (Atm<sup>-/-</sup>nu<sup>-/-</sup>; 129S6/SvEvTac-Atm<sup>tm1Awb</sup>/J, Jackson Laboratory, Maine, USA) with Balb/c nude males (Atm<sup>-/-</sup>nu<sup>-/-</sup>; Charles River, Harlow, UK) produced Atm<sup>-/-</sup>nu<sup>-/-</sup> heterozygotes. Female Atm<sup>-/-</sup>nu<sup>-/-</sup> progeny from the first generation underwent a second mating with male Atm<sup>-/-</sup>nu<sup>-/-</sup> to obtain nude Atm heterozygotes (Atm<sup>-/-</sup>nu<sup>-/-</sup>). Finally, a third mating of second generation Atm<sup>-/-</sup>nu<sup>-/-</sup> males with first generation Atm<sup>-/-</sup>nu<sup>-/-</sup> females produced Atm<sup>-/-</sup>nu<sup>-/-</sup> offspring.

**Adoptive transfer of Atm<sup>-/-</sup>nu<sup>-/-</sup> lymphomas and drug treatment**

Lymphomas arising from Atm<sup>-/-</sup>nu<sup>-/-</sup> mice (2x10<sup>6</sup> cells) were subcutaneously injected into NOD/LtSz-SCID/IL2γ<sup>tm1Wjl</sup>/SzJ (NSG) mice (Charles River). Upon attaining average tumor volumes of 100mm<sup>3</sup>/mouse, mice were randomized into 4 oral gavage treatment arms receiving mycophenolate mofetil (MMF, 100mg/kg/day; Selleckchem, Munich, Germany), adavosertib (AZD1775, 30mg/kg/day; AstraZeneca, Cambridge, UK), combined MMF and AZD1775, or vehicle; respectively. Animals were euthanized when tumor volume exceeded 1250mm<sup>3</sup>.

**Cell lines**

Cell lines were established without Epstein-Barr virus infection, by culturing single-cell suspensions of Atm<sup>-/-</sup>nu<sup>-/-</sup> lymphomas (1x10<sup>6</sup>), in RPMI containing 15% FCS, 1% pyruvate,
1% NEAA/β-mercaptoethanol (50µM) and 1% penicillin/streptomycin (Life Technologies, Inchinnan, UK). Their immunophenotype and clonal relationship with the primary tumor were confirmed (Table S1).

Human and Eμ-Myc cell lines were cultured according to standard protocols (Supplementary Methods). Lymphoblastoid cell lines (LCL) were previously generated from samples obtained from A-T patients and healthy volunteers. Studies were approved by the West Midland, Coventry and Warwickshire Research Ethics Committee (REC: 20//WM/0098) and performed in accordance with local ethical guidelines. Written informed consent was obtained from all patients in accordance with the Declaration of Helsinki.

**CRISPR/Cas9-mediated loss-of-function screen**

Cell lines were modified to stably express Cas9 and infected with the two-vector (lentiCas9-Blast and lentiGuide-Puro) lentiviral GeCKO v2.0 CRISPR knockout system (Addgene, MA) consisting of 130,209 pooled single-guide RNAs (sgRNA) targeting 20,661 genes and 1,000 control sgRNA. Cells were cultured at optimal cell number (1-6x10^6) to maintain ≥1000-fold coverage of the CRISPR sgRNA library. At day 0 and 18 (~14 doublings), DNA isolated from harvested viable cells was subjected to targeted deep sequencing of sgRNA using NextSeq HIGH 150 v2.5 kits on the NextSeq 500 sequencer (Illumina). The MAGeCK tool was used to determine sgRNA that were significantly depleted at day 18 compared to day 0 representing those targeting genes that were essential for cell survival ('hits'). KEGG pathway analysis was performed as for RNA-seq data.

**Statistical analysis**

Statistical analyses were performed using GraphPad Prism 9.2.0 (La Jolla, CA).

**Results**

*Atm<sup>−/−</sup> nu<sup>−/−</sup> mice develop B-cell lymphomas with complex karyotype that closely model human activated B-cell-like (ABC) and germinal center B-cell-like (GCB) DLBCL*

To model B-NHL that results from constitutional *ATM* loss, we generated a novel athymic *Atm*-deficient model (*Atm<sup>−/−</sup> nu<sup>−/−</sup>) (Figure 1A). This overcomes an inherent limitation with *Atm<sup>−/−</sup>*
mice which develop lethal thymoma in early life (<16 weeks) precluding their use to study B-cell lymphomagenesis.20,21

Crossing Atm−/− mice with nu−/− mice prevented thymoma development, leading to prolonged survival of Atm−/−nu−/− mice, irrespective of whether death was caused by tumor or other causes, mostly infection (median survival 13 vs 23 weeks for Atm−/− vs Atm−/−nu−/− mice) (Figure 1B; Figure S1). Atm−/−nu−/− mice instead developed B-NHL, reminiscent of patients with A-T.14,15 B-cell lymphomas emerged with 24% penetrance, manifesting in splenomegaly, frequent hepatomegaly and nodal involvement that arose at a median of 25 weeks (range 7-69) (Figure 1B). These lymphomas histologically and immunophenotypically resembled human DLBCL, with 6 of 14 lymphomas demonstrating Ki-67 >50%, and harboring identifiable clonal IGHV-D-J gene rearrangements (Figure 1C; Table S1).

B-cell lymphomagenesis in the context of constitutional ATM loss has also been recapitulated by the ATMKO.CD3εKO model generated by interbreeding Atm-deficient mice with CD3ε-knockout mice.18 However, unlike the ATMKO.CD3εKO model wherein T-cell immunity is absent,18 T-cells are present in the Atm−/−nu−/− model, albeit at markedly reduced level (Figure 2A), akin to patients with A-T.22 Early progenitor B-cell number retention (B220+CD43+) coupled with a trend towards reduced levels of more mature B-cell populations in the bone marrow (Figure 2A) and spleen (data not shown) in the Atm−/−nu−/− model resembles A-T patients impaired B-cell development.16 Moreover, in contrast to ATMKO.CD3εKO mice which were unable to form germinal centers and exclusively developed lymphomas resembling ABC DLBCL,18 germinal centers were preserved in Atm−/−nu−/− mice (Figure 2B). While the majority of Atm−/−nu−/− lymphomas displayed gene expression signatures characteristic of human ABC DLBCL, some resembled GCB DLBCL (Figure 2C; Figure S2A,B).23,24 Atm−/−nu−/− mice therefore developed lymphomas that reflect the spectrum of DLBCL observed in patients harboring defective ATM.9,13,24

Atm−/−nu−/− lymphomas exhibited a diverse landscape of complex karyotypic alterations (mean 10; range 5-17) indicating substantial intertumoral and intratumoral genetic heterogeneity (Figure 2D; Figure S2C). These alterations included chromosomal translocations and whole chromosome gains and losses, with the majority being subclonal. As found in human DLBCL,25 IgH and Myc alterations were evident with Myc duplication present in 2 of 6 Atm−/−nu−/− lymphomas (Figure S2C; Table S2). These features suggest a high level of genomic instability and clonal evolution in Atm−/−nu−/− lymphomas likely driven in part by Atm loss. Taken together, our Atm−/−nu−/− mice provide a robust model for the elucidation of pathogenic mechanisms and therapeutic targets in human DLBCL.
**Atm**<sup>−/−</sup>**nu**<sup>−/−</sup> lymphomas are characterized by MYC activation

To decipher the biological processes underlying B-cell lymphomagenesis in Atm<sup>−/−</sup>nu<sup>−/−</sup> mice, we characterized the transcriptomic landscape of Atm<sup>−/−</sup>nu<sup>−/−</sup> lymphomas. RNA-seq data revealed 1493 upregulated and 1010 downregulated genes in Atm<sup>−/−</sup>nu<sup>−/−</sup> lymphomas relative to healthy splenic B-cells from Atm<sup>+/+</sup>nu<sup>−/−</sup> and Atm<sup>+/−</sup>nu<sup>−/−</sup> mice (Figure 3A; Table S3).

Genes involved in cell cycle progression (e.g. Ccnf, Cdk6, Ccnb1, Cdca5), mitosis (e.g. Kihl13, Psrl1, Spdl1, Kifc1), DNA replication (e.g. Orc1, Mcm6, Pole, Prim1, Rfc4) and cellular metabolism (e.g. Mgll, Gpt2, Uqcr10, Cox4i2) were among the most significantly upregulated in Atm<sup>−/−</sup>nu<sup>−/−</sup> lymphomas (Figure 3B; Table S4), reflecting the loss of ATM-dependent cell cycle checkpoints and resultant high proliferation rate. Concurrently, key genes mediating homologous recombination repair (e.g. Rad51, Brca1, Pole), chromatin modification (e.g. Ezh2, Cenpa), replication stress response (e.g. Wee1, Chk1) and nucleotide biosynthesis (e.g. Rtm2, Tyms) were some of the most significantly overexpressed. Finally, reflecting the malignant properties of transformed B-cells in Atm<sup>−/−</sup>nu<sup>−/−</sup> mice, tumor suppressor genes (e.g. Txnip, Cul9) and genes involved in normal B-cell development, signaling and activation (e.g. Cr2, Akt3, Icosl, Cx3cr1) as well as antigen presentation (e.g. Cd1d1) were significantly downregulated, whereas genes that promote tumor immune evasion (e.g. Ctla4) were upregulated (Tables S4 and 5).

An association between ATM loss, aberrant gene rearrangements and MYC deregulation has been previously established. Moreover, ATM-dependent DNA damage response counteracts the tumorigenic effect of MYC activation, providing the basis for co-operation between ATM and MYC during tumorigenesis. Concurring with this notion and the presence of Myc duplications in Atm<sup>−/−</sup>nu<sup>−/−</sup> lymphomas, GSEA analysis of RNA-seq data demonstrated that MYC targets, and MYC-induced E2F targets, were among the most enriched gene sets in these lymphomas (Figure 3C,D; Figure S3A,B; Table S6), which was consistent with elevated MYC protein expression (Figure 3E; Figure S3C). As replication stress is a principal consequence of MYC dysregulation, upregulation of replication stress response genes in Atm<sup>−/−</sup>nu<sup>−/−</sup> lymphomas may be a consequence of upregulated MYC in the majority of these lymphomas. Other drivers, such as those involved in repair of DNA lesions induced by MYC-driven replication stress, may also play a role. The transcriptomic landscape of Atm<sup>−/−</sup>nu<sup>−/−</sup> lymphomas thus identified potentially targetable biological features, including DNA repair, a requirement for nucleotide biosynthesis due to replicative stress, and dysregulated MYC that likely underpin ATM-defective DLBCL oncogenesis (Figure 3F).
**Genome-wide CRISPR/Cas9 screen identifies nucleotide biosynthesis as a cellular dependency of Atm<sup>−/−</sup>nu<sup>−/−</sup> lymphomas**

We hypothesized that in a significant number of these lymphomas, heightened replication stress, due in part to MYC upregulation, could render these tumors dependent upon nucleotide biosynthesis. To systematically identify potentially actionable lymphoma-specific dependencies within our Atm<sup>−/−</sup>nu<sup>−/−</sup> model, we performed a genome-scale CRISPR/Cas9-mediated loss-of-function screen on two Atm<sup>−/−</sup>nu<sup>−/−</sup> lymphoma derived cell lines (50F2 and AN017) (Figure 4A).

At the optimal false discovery rate (FDR)-adjusted p-value threshold of 0.05 that produced a manageable gene output, 1000 and 340 hits were identified in 50F2 and AN017 respectively, with 197 hits common to both (Figure 4B,C; Table S7). Consistent with the observed MYC dysregulation, analysis of depleted sgRNA revealed a Myc dependency (rank 861; fold-change: -0.742) as well as dependency on key biological processes common to both cell lines (Figure 4D,E; Figure S4; Table S8). These included genes involved in DNA repair (e.g. Parp1, Rad50, Rad51, Rnaseh2c, Mcm7), DNA replication (e.g. Pold2, Mcm7, Rnaseh2c), telomere maintenance e.g. (Pot1, Telo2) and cell cycle regulation (e.g. Cdk6, Fam58b), consistent with cellular dependence on alternative genome maintenance regulators upon Atm loss. Notably, the top hits identified from the CRISPR/Cas9 screen were also highly enriched in genes mediating nucleotide biosynthesis, including those encoding for the enzymes Tyms, Umups, Cmpk1, Cad and Ppat that play key roles in deoxynucleotide triphosphate (dNTP) production, as well as other important components within the purine biosynthesis pathway (Figure 4F,G). These observations therefore support the notion that both Myc activity and nucleotide biosynthesis are major cellular dependencies of Atm<sup>−/−</sup>nu<sup>−/−</sup> lymphomas.

**Nucleotide depletion induces replication stress overload and tumor-specific lethality in MYC-dependent Atm<sup>−/−</sup>nu<sup>−/−</sup> lymphomas**

The identification of MYC and nucleotide biosynthesis as cellular dependencies, together with evidence for their upregulation as part of a heightened replication stress response, raises the question of whether these lymphomas are sensitive to MYC inhibition and depletion of cellular nucleotide pools through inhibition of nucleotide biosynthesis. To address this, we examined the effect of MMF, an inhibitor of de novo purine biosynthesis, on Atm<sup>−/−</sup>nu<sup>−/−</sup> lymphomas. Moreover, since Wee1 and Rrm2 were among the most significantly overexpressed genes in Atm<sup>−/−</sup>nu<sup>−/−</sup> lymphomas, we also evaluated the effect of
the WEE1 inhibitor, AZD1775, which can promote degradation of RRM2, a subunit of ribonucleotide reductase that is essential for dNTP biosynthesis.\textsuperscript{37}

\textit{In vitro} MYC inhibition of an $Atm^{-\nu^{-}}$ lymphoma-derived cell line conferred significant cytotoxicity (Figure 5A). Furthermore, treatment of three $Atm^{-\nu^{-}}$ lymphoma-derived cell lines with physiologically achievable concentrations of MMF or AZD1775 resulted in dose-dependent cytotoxicity, which was rescued via MYC inhibition (AZD) or addition of exogenous dNTP (MMF), consistent with the increased requirement for nucleotide biosynthesis caused by MYC activation (Figure 5B-D). Notably, MMF and AZD1775-induced cytotoxicity was also attained in $Atm$ wild-type, $E\mu$-Myc-driven tumors that resemble human Burkitt lymphoma (Figure S5A).\textsuperscript{38}

We reasoned that nucleotide depletion to catastrophic levels through concerted actions of MMF and AZD1775 in $Atm^{-\nu^{-}}$ lymphomas might enhance lethality. Indeed, AZD1775 was synergistic when used in combination with MMF (Figure 5B,E), which was reversible upon MYC inhibition, dNTP supplementation or RRM2 upregulation via the specific NEDD8 inhibitor (NEDDi), pevonedistat (Figure 5C,D,F). As expected, AZD1775 treatment led to attenuated RRM2 levels in $Atm^{-\nu^{-}}$ lymphoma cells and a derived-cell line (50F2) and activation of the replication stress response (Figure 5G; Figure S5B). The latter was evidenced by the induction of CHK1 phosphorylation, consistent with the exacerbation of replication stress upon nucleotide depletion.

To confirm the \textit{in vivo} efficacy of nucleotide depletion as a therapeutic strategy, administration of MMF and AZD1775, alone or combined, to mice engrafted with an $Atm^{-\nu^{-}}$ lymphoma (AT15c) was well-tolerated. Combined treatment significantly reduced tumor volume and delayed tumor growth as none of the tumors attained the maximum permitted tumor volume within this treatment group (Figure 5H).

The cytotoxicity of the nucleotide biosynthesis inhibitors was exerted via apoptosis (Figure 6A,B). This is likely due to replication stress overload as evidenced by impeded replication fork progression, resulting in fork stalling with compensatory initiation of nearby dormant origins upon combined MMF and AZD1775 treatment (Figure 6C).\textsuperscript{39,40} The latter is supported by the retention of $Atm^{-\nu^{-}}$ lymphoma cells in quiescent S-phase with the accumulation of partially-replicated DNA and lethal DNA damage (Figure 6D-F; Figure S5C).\textsuperscript{41} Our observations in $Atm^{-\nu^{-}}$ lymphomas therefore provided conceptual proof of nucleotide depletion as a viable therapeutic strategy for DLBCL harboring MYC dysregulation associated with $ATM$ loss.
MYC overexpression broadly sensitizes human DLBCL cells to nucleotide depletion with AZD1775

Human DLBCL may exhibit MYC dysregulation concurrently with ATM disruption. However, the majority of DLBCL with MYC overexpression do not exhibit ATM loss. To determine whether the use of nucleotide depletion as a therapeutic strategy can be broadly extended to human DLBCL harboring MYC dysregulation associated with pathogenic mechanisms beyond ATM loss, we set out to validate such a therapeutic strategy within these contexts.

Human DLBCL cell lines were sensitive to MYC inhibition and physiologically achievable doses of MMF and AZD1775, which for AZD1775, correlated with MYC upregulation (Figure 7A-C; Figure S3C; Figure S6A,B). Similar to Atm$^-$nu$^-$ lymphomas, synergism was evident upon AZD1775 and MMF co-treatment particularly in high MYC-expressing cell lines (Figure 7C,D; Figure S6A), with MYC inhibition reducing cytotoxicity (Figure 7E). In contrast, loss of ATM did not impact upon MMF or AZD1775 sensitivity in A-T patient-derived LCL cells nor in CLL-derived CII cells with ATM knockdown (Figure S6C,D). Moreover, the ATM-deficient DLBCL cell line (Farage) was AZD1775-resistant (Figure 7C; Figure S6A,E). Upon mining the Cancer Dependency Map (DepMap) data that uncovers gene dependencies in hundreds of cancer cell lines we observed a significant inverse correlation between protein expression of two nucleotide biosynthesis genes (CAD, UMPS) and MYC, but not ATM (Figure 7F). In addition, mining published human DLBCL RNA-seq datasets revealed that, compared to germinal center B-cells, ABC DLBCL concurrently express significantly reduced ATM and elevated MYC levels. Furthermore, MYC expression is higher in the ABC than the GCB DLBCL cohort whilst expression of a purine/pyrimidine biosynthesis gene-set is elevated in ABC DLBCL in comparison to both GCB DLBCL and germinal center B-cells (Figure S6F). Thus, nucleotide biosynthesis inhibition may be particularly relevant for an ABC DLBCL subgroup characterized by upregulated MYC. Consistent with this notion, a high-MYC expressing human Burkitt lymphoma cell line was more sensitive to nucleotide biosynthesis inhibition than a low-MYC expressing cell line (Figure S7).

Akin to Atm$^-$nu$^-$ lymphoma cells, cytotoxicity of these nucleotide biosynthesis inhibitors was exerted via apoptosis in high MYC-expressing human DLBCL (OC-ILY3) (Figure 8A,B), likely due to exacerbation of replication stress as evidenced by retention of cells in quiescent S-phase and activation of the replication stress response (Figure 8C-E).

Taken together, these results show that response to nucleotide depletion in human lymphoma is influenced by MYC expression rather than ATM mutation status, thus
demonstrating its broad applicability as a therapeutic approach independent of the mechanism underlying MYC dysregulation. Also, whilst the Atm<sup>-/-</sup>nu<sup>-/-</sup> lymphomas and derived cell lines provide a model for DLBCL developed by A-T patients this could potentially also be useful for patients with high MYC-expressing DLBCL without A-T.

**Discussion**

High-grade B-NHL is the commonest tumor type in patients with ataxia-telangiectasia, representing 37%-53% of cancer diagnoses in these individuals. However, only a proportion of A-T patients develop tumors, and the mechanisms of B-cell tumorigenesis underlying ATM loss remains unresolved. Moreover, the use of chemoradiotherapy for lymphoma treatment can be especially toxic for these patients owing to their inherent cellular chemoradiosensitivity. Hence, the identification of therapeutic targets and development of alternative cancer treatments represents a critical unmet need.

In this context, our Atm<sup>-/-</sup>nu<sup>-/-</sup> murine model closely recapitulates conditions under which lymphomagenesis occurs in human A-T including thymic aplasia and retention of a low-level of T-cells arrested at the CD3<sup>+</sup>CD8<sup>+</sup> and CD3<sup>+</sup>CD4<sup>+</sup> differentiation stage. Importantly, Atm<sup>-/-</sup>nu<sup>-/-</sup> mice retained germinal centers and developed GCB as well as ABC DLBCL, reminiscent of the phenotypic spectrum in ATM-defective human DLBCL. To enable unbiased discovery of additional pathogenic processes and targetable lymphoma addictions, we systematically interrogated our Atm<sup>-/-</sup>nu<sup>-/-</sup> model with genome-scale technology incorporating RNA-seq and CRISPR/Cas9 loss-of-function screens, approaches that have not previously been utilized to study ATM-defective DLBCL.

Our analysis uncovered a MYC-driven lymphoproliferation occurring in the context of constitutional ATM loss that characterizes A-T. However, whilst ATM inactivation initiates the genesis of Atm<sup>-/-</sup>nu<sup>-/-</sup> lymphomas, it remains unclear whether ATM deficiency is an ongoing dependency in these tumors. Furthermore, well-known genetic mechanisms involving chromosomal rearrangements or gene amplifications only give rise to ~35% of MYC overexpressing high-grade B-NHL. Likewise, genetic disruptions involving Myc were observed in some Atm<sup>-/-</sup>nu<sup>-/-</sup> lymphomas but were absent in other instances of MYC dysregulation. Thus, future studies are required to determine the long-term effect of ATM deficiency on lymphomagenesis and the mechanisms that contribute to MYC activation in this murine model.
Our analysis revealed actionable dependencies beyond B-cell receptor signaling in ATM-defective DLBCL. In fact, from our CRISPR/Cas9 screens we observed dependency on key B-cell receptor signaling genes in only one of two evaluated Atm−/− nu−/− lymphoma cell lines (50F2). On the contrary, nucleotide biosynthesis emerged as one of the most prominent dependencies in both lymphoma lines, alongside DNA repair, DNA replication and cell cycle regulation, which were also significantly upregulated processes in our RNA-seq dataset. We showed that nucleotide metabolism in the context of Atm loss is a MYC-dependent vulnerability, which can be effectively targeted by nucleotide depletion through the synergistic actions of MMF and AZD1775. Our findings are consistent with a mechanistic model in which MYC induces replication stress by multiple transcription-dependent and transcription-independent mechanisms. Moderate levels of replication stress support tumor progression via generation of genomic instability whilst excessive levels are prevented by MYC-regulated nucleotide biosynthesis that becomes essential for tumor survival. Combining MMF and AZD1775 potently inhibits nucleotide biosynthesis, leading to depletion of cellular dNTP that exacerbates replication stress. In turn, the accumulation of replication stress to catastrophic levels results in lymphoma lethality (Figure 8F). It remains to be determined whether other causes of replication stress or different mechanisms can render lymphoma cells dependent on nucleotide biosynthesis in the absence of MYC upregulation, as observed in two DLBCL cell lines with low MYC expression.

Targeted therapies, such as ibrutinib, have been associated with disappointing responses coupled with possible enrichment of cells overexpressing MYC targets in ibrutinib-resistant DLBCL. We confirmed the broad applicability of nucleotide depletion as a therapeutic strategy for MYC-driven DLBCL independent of ATM status in human DLBCL models. In this regard, a previous study showed that inhibition of phosphoribosyl pyrophosphate synthetase 2, an enzyme essential for purine biosynthesis, is synthetically lethal in MYC-driven murine lymphoma. Herein, we demonstrated a complementary strategy to inhibit nucleotide biosynthesis in DLBCL through synthetic lethality between RRM2 depletion and MYC overexpression, which is potentiated in the presence of MMF (Figure 8F). We showed that depletion of RRM2, a ribonucleotide reductase subunit essential for nucleotide biosynthesis, can be achieved through AZD1775, the WEE1 inhibitor under active clinical investigation in DLBCL (NCT02465060, NCT04439227). Indeed, a recent study demonstrating selectivity of AZD1775 monotherapy against MYC-overexpressing DLBCL lends further support to a synthetically lethal interaction between MYC overexpression and RRM2 loss. While clinical trials in solid tumors showed AZD1775 to be generally well-tolerated, our findings support the clinical evaluation of the AZD1775-MMF combination in DLBCL, including among ataxia-telangiectasia patients. Our results also support the investigation of MYC
overexpression as a predictive biomarker of response to inform patient selection into these trials.

Finally, our CRISPR/Cas9 screen identified other core components within the purine or pyrimidine biosynthetic pathway that could serve as synthetically lethal partners with MYC overexpression and/or ATM loss, and therefore deserve further investigation as therapeutic targets. These include phosphoribosyl pyrophosphate amidotransferase (PPAT), carbamoylphosphate synthetase (CAD), thymidylate synthetase (TYMS) and uridine 5'-monophosphate synthase (UMPS). Collectively, our findings highlight nucleotide metabolism as a compelling therapeutic vulnerability with potential for further development into a novel treatment paradigm for clinically high-risk, MYC-driven lymphoma. This approach is garnering interest in haemato-oncology with a dihydroorotate dehydrogenase inhibitor (BAY2402234) already in a phase I clinical trial for myeloid malignancies.53,54
References


Figure legends.

**Figure 1.** *Atm*<sup>−/−</sup>*nu*<sup>−/−</sup> mice develop B-cell lymphomas that resemble human diffuse large B-cell lymphoma (DLBCL). (A) Schematic diagram summarizing experimental studies to characterize the *Atm*<sup>−/−</sup>*nu*<sup>−/−</sup> murine model with the aim to identify therapeutic targets that can be translated to human B-cell non-Hodgkin lymphoma (B-NHL). (B) Kaplan-Meier curves displaying prolonged overall survival of *Atm*<sup>−/−</sup>*nu*<sup>−/−</sup> (n=97) and *Atm*<sup>+/+</sup>*nu*<sup>−/−</sup> (n=17) mice in comparison to *Atm*<sup>−/−</sup>*nu*<sup>+</sup> (n=23) and *Atm*<sup>−/−</sup>*nu*<sup>+</sup> (n=13) mice (P<0.0001). Inset: *Atm*<sup>−/−</sup>*nu*<sup>−/−</sup> littermates (7-69 wks old) had enlarged spleens and livers in comparison to their *Atm*<sup>−/−</sup>*nu*<sup>+</sup> and *Atm*<sup>+/+</sup>*nu*<sup>−/−</sup> counterparts. (C) Immunohistology and morphology indicates that tumors from *Atm*<sup>−/−</sup>*nu*<sup>−/−</sup> mice are lymphomas of B-cell origin resembling human DLBCL. Representative images of sections (original magnification x10 and insets x40) from two representative *Atm*<sup>−/−</sup>*nu*<sup>−/−</sup> DLBCL (5F1, 519) stained with haematoxylin/eosin (H&E) as well as for B-cell (CD10, CD20, B220), T-cell (CD3), proliferation (Ki67, CD10) and DLBCL (PAX5, IRF4, FOXP1, CD10) markers are depicted.

**Figure 2.** B-cell lymphomas that develop in *Atm*<sup>−/−</sup>*nu*<sup>−/−</sup> mice have a complex karyotype that resembles human activated B-cell-like (ABC) and germinal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL). (A) FACS analysis of splenic T-cell and bone marrow B-cell populations of 6-8 week old mice revealed reduced but not completely absent T-cell populations in *Atm*<sup>+/+</sup>*nu*<sup>−/−</sup> (n=4) and *Atm*<sup>−/−</sup>*nu*<sup>−/−</sup> (n=5) mice compared to *Atm*<sup>+/+</sup>*nu*<sup>+/+</sup> (n=16), *Atm*<sup>−/−</sup>*nu*<sup>−/−</sup> (n=19) and *Atm*<sup>−/−</sup>*nu*<sup>+/+</sup> (n=6). T-cells were arrested at the CD3<sup>+</sup>CD8<sup>+</sup> and CD3<sup>+</sup>CD4<sup>+</sup> differentiation stage. Significantly fewer precursor (B220<sup>+</sup>CD43<sup>−</sup>) and transitional (B220<sup>high</sup>CD43<sup>IgM</sup>) B-cells were evident in the bone marrow of *Atm*<sup>−/−</sup>*nu*<sup>−/−</sup> mice compared to their *Atm*<sup>−/−</sup>*nu*<sup>+/+</sup> and/or *Atm*<sup>−/−</sup>*nu*<sup>+</sup> counterparts, whilst the levels of progenitor (B220<sup>−/med</sup>CD43<sup>IgM</sup>) B-cells were similar across all genotypes. Immature (B220<sup>−/med</sup>CD43<sup>−/IgM</sup>) B-cell levels were highly variable even within genotypes. Data are presented as mean ± SEM. Statistical significance, ascertained by one-way ANOVA with Tukey post-hoc test, is denoted by: *P<0.05, **P<0.01, ***P<0.005, ****P<0.001, *****P<0.0005, ******P<0.0001. (B) Germinal centers (arrows): albeit with perturbed morphology and larger than normal; were evident in various lymph nodes (LN) and gut mucosa of *Atm*<sup>−/−</sup>*nu*<sup>−/−</sup> mice. Representative images of sections (original magnification: x5, pancreas; x10, neck, intestine) stained with H&E are depicted. (C) Comparison of ribonucleic acid (RNA)-seq data of *Atm*<sup>−/−</sup>*nu*<sup>−/−</sup> lymphomas (n=11) and control splenic B-cells from *Atm*<sup>−/−</sup>*nu*<sup>−/−</sup> and *Atm*<sup>+/+</sup>*nu*<sup>−/−</sup> mice (n=2) against published RNA-seq datasets of human ABC DLBCL and healthy control germinal center (GC) B-cells<sup>55,56</sup> suggests that the majority of *Atm*<sup>−/−</sup>*nu*<sup>−/−</sup> lymphomas cluster with human ABC DLBCL.<sup>9</sup> (D) Left panel: Specific translocations involving *IgH* and *Myc* were assessed by M-Fluorescence in situ hybridization
(FISH) in six Atm−/−nu−/− lymphomas. The representative example shown (5F3) harbored Myc gain and IgH loss as indicated by the arrows (IgHa, red; IgHV, green; Myc, red). Right panel: The circos plot summarizing the chromosomal alterations for the 6 Atm−/−nu−/− B-cell lymphoma revealed an absence of common translocations. Chromosomes are indicated by the numerals and annotated with lymphoma relevant genes localized in the regions affected by chromosomal alterations.

Figure 3. Atm−/−nu−/− lymphomas display a transcriptional profile characterized by MYC activation. (A) RNA-seq analysis of Atm−/−nu−/− lymphomas (n=11) and control splenic B-cells from Atm−/−nu−/− and Atm−/−nu−/− mice (n=2) revealed differentially expressed genes in Atm−/−nu−/− lymphomas; 1493 upregulated (red) and 1010 downregulated (blue). (B,C) Biological processes that are the most significantly upregulated in Atm−/−nu−/− lymphomas compared to control splenic B-cells as revealed by (B) Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway and (C) Gene Set Enrichment Analysis (GSEA) hallmark pathway analyses. (D) Comparison of the murine RNA-seq data to human ABC (n=252), GCB (n=278) and unknown (n=94) DLBCL,9 stratified according to MYC target gene expression: MYC high (n=201) and low (n=436)57 reveals that a high proportion of Atm−/−nu−/− lymphomas align with high MYC-expressing human DLBCL. (E) MYC expression is upregulated in the majority of Atm−/−nu−/− lymphomas (5F3, 50F2, 703, AN017, AN009) in comparison to murine basal controls: M3+/+ (Atm+/+nu+/+), Nu−/−(Atm+/−nu−/−), F2+/+ (Atm−/+nu+/+); MYC positive control: L41F1−/−(Atm−/−nu+/+); and also human ATM isogenic CII CLL cell lines, LCLs derived from healthy and ataxia-telangiectasia (A-T) individuals with WILL-2 (human DLBCL) as a MYC positive control on a separate gel. (F) Summary of the most relevant significantly upregulated (red) and downregulated (blue) genes and biological processes in Atm−/−nu−/− lymphomas.

Figure 4. Genome-wide CRISPR/Cas9 screen identifies nucleotide biosynthesis as a cellular dependency of Atm−/−nu−/− lymphomas. (A) Identification of cellular dependencies by genome-scale clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9-mediated loss-of-function screens of two cell lines established from Atm−/−nu−/− lymphomas (50F2 and AN017). (B) Cumulative number of hits (from 21513 potential genes) at various false discovery rates (FDR) in each individual cell line and common to both (combined). A 5% FDR (FDR < 0.05) was set for all further analysis. (C) The number of mutually exclusive and common hits between the two cell lines at FDR < 0.05. (D) Major biological processes represented by the discovered hits from the CRISPR/Cas9 screen. These processes were also upregulated in Atm−/−nu−/− lymphomas as evidenced from RNA-seq data. (E) KEGG pathway analysis of hits common to both Atm−/−nu−/− lymphoma cell lines revealing essential
cellular dependencies. (F,G) Hits identified within the purine biosynthesis pathway (dark orange), the most significantly affected biological process, that represent potential therapeutic targets.

**Figure 5. Nucleotide depletion induces replication stress overload and lethality in MYC-dependent Atm−/nu− lymphomas.** (A) Exposure for 72h, of the Atm−/nu− lymphoma cell line, 50F2, to a MYC inhibitor (MYCi, MYCi361); at doses reported (Selleckchem) to specifically inhibit MYC activity; led to significant toxicity as measured by CellTitre-Glo assay. (B-D) Exposure of Atm−/nu− lymphoma cell lines (703, 5F3, 50F2) to mycophenolate mofetil (MMF) and/or adavosertib (AZD1775) for 72h led to significant toxicity as measured by (B) Alamar Blue, (C) CellTitre-Glo or (D) Propidium Iodide (PI) exclusion that could be rescued by (C) inhibition of MYC or (D) addition of exogenous nucleosides. (C) Surviving fraction was normalized to the appropriate MYCi dose to highlight any rescue from MMF and/or AZD1775 toxicity. (E) Combining MMF and AZD1775 results in synergistic cytotoxicity. (F) The cytotoxic effect of MMF and AZD1775 can be ameliorated by upregulation of RRM2 via NEDD8 inhibition (MLN4924, pevonedistat). (C,D,F) Cell lines were treated with MMF doses corresponding to the EC$_{50}$ and 400nM AZD1775. (G) AZD1775 (400nM; 72h) exerts its effects via depletion of RRM2 and subsequent exacerbation of replication stress, on an Atm-deficient background, via reduction of ATR-mediated deoxyribonucleic acid (DNA) repair activity in Atm−/nu− lymphoma cell lines. Irradiated (IR, 6Gy, 30min) A-T patient-derived LCLs serve as a positive control. (H) Nucleotide depletion with AZD1775 and MMF demonstrated significant activity in vivo. NSG mice harboring adoptively transferred Atm−/nu− lymphoma (AT15c) were administered vehicle (n=4), MMF (100mg/kg; n=5), AZD1775 (30mg/kg; n=5), or a combination of MMF and AZD1775 (n=6) via oral gavage for 7 days. Overall tumor size was significantly smaller in animals receiving combination therapy, in comparison to AZD1775 alone. Data are presented as mean ± SEM of (A,C) 50F2, (B,D,F) the three cell lines (703, 5F3, 50F2) or (H) mice per treatment arm. All cytotoxicity experiments were performed at least in quadruplicate. Statistical significance versus Vehicle (•), MMF (†), AZD1775 (+), MYCi, nucleoside or NEDDi (‡), was ascertained by matched multi-comparison (A) one-way or (B,C,D,F,H) two-way ANOVA with Tukey post-hoc test denoted by: *$P \leq 0.05$, **$P \leq 0.01$, ***$P \leq 0.005$, ****$P \leq 0.0005$, *****$P \leq 0.0001$.

**Figure 6. Nucleotide depletion induces replication stress-mediated apoptosis in Atm−/nu− lymphomas.** (A,B) Exposure (72h) of Atm−/nu− lymphoma cell lines (703, 5F3, 50F2) to vehicle, MMF (250nM) or AZD1775 (400nM), alone or in combination, led to cell death primarily via apoptosis. (A) Apoptosis was distinguished from mitotic catastrophe by 4',6-
diamidino-2-phenylindole (DAPI)*/Lamin B*/phospho (p)-Histone H3-S10– immunofluorescence staining in the former, and DAPI*/Lamin B*/p-Histone H3-S10– staining in the latter. (B) Apoptosis was confirmed by Annexin V (AxV)/PI status: viable (AxV–/PI–), early apoptotic (AxV+/PI–), late apoptotic (AxV+/PI+), secondary necrotic (AxV–/PI+). (C) Replication fork progression in Atm–nu– lymphomas measured by DNA fibre analysis; was significantly impeded by combination treatment with AZD1775 and MMF. (D) Cell cycle profiles of an Atm–nu– lymphoma (50F2, n=3) showed an accumulation of tumor cells in S-phase upon combination treatment with AZD1775 and MMF. (E) Replicating (active, EDU+) and non-replicating (inactive, EDU–) cells in S-phase were distinguished by EDU positivity. In an Atm–nu– lymphoma (50F2, n=3), combined treatment with AZD1775 and MMF led to accumulation of non-replicating cells residing in S-phase. (F) The proportion of γH2AX+ cells in non-replicating (inactive, EDU–) S-phase was determined by flow cytometry. Combined treatment with AZD1775 and MMF resulted in γH2AX accumulation in Atm–nu– lymphoma cells (50F2, n=3). Data are presented as mean ± SEM of (A-C) the three cell lines (703, 5F3, 50F2) or (D-F) 50F2. All experiments were performed at least in triplicate. Statistical significance ascertained by (A-E) matched multi-comparison two-way ANOVA with Tukey post-hoc test and (F) repeat-measures matched multi-comparison one-way ANOVA with Tukey post-hoc test denoted by: *P≤0.05, **P≤0.01, ***P≤0.005, ****P≤0.001, *****P≤0.0005, ******P≤0.0001. (B) Statistical significance of Viable (*), Early Apoptotic (†), Late Apoptotic (+), or Necrotic (‡) cells. (E) Inactive cell comparison (+).

Figure 7. High MYC expression sensitizes human DLBCL cells to AZD1775 induced nucleotide depletion. (A) Exposure of OCI-LY3, the human DLBCL cell line with high MYC expression to the MYC inhibitor (MYCi, MYCi361); at doses reported (Selleckchem) to specifically inhibit MYC activity; for 72h, led to significant toxicity as measured by CellTitre-Glo assay (n=5). (B) Exposure of 11 human DLBCL cell lines with varying MYC protein expression; determined by Western blot with band intensities quantified using Image J normalized to VINCULIN; to physiologically attainable concentrations of MMF or AZD1775 indicated a correlation between MYC expression (low, blue; intermediate, orange; high, green) and increased AZD1775 cytotoxicity as measured by the CellTitre-Glo assay. (C) Dose response curves in two representative DLBCL cell lines show significant cytotoxicity with combined MMF and AZD1775 treatment in high MYC-expressing OCI-LY3 but not low MYC-expressing Farage. (D) Fold-change representing the ratio of the surviving fraction following exposure to various AZD1775+MMF dose combinations versus AZD1775 alone for the 11 human DLBCL cell lines. A fold change <0.8 indicates synergism and >1.2 indicates antagonism. Cell lines expressing high levels of MYC (green) are synergistically sensitive to the combined treatment. (E) Treatment of the OCI-LY3 cell line with a MYC inhibitor (MYCi,
MYCi361) reduced its sensitivity to single-agent MMF (1000nM) and combined treatment with MMF (1000nM) and AZD1775 (200nM) (n=5). Surviving fraction was normalized to the appropriate MYCi dose to highlight any rescue from MMF and/or AZD1775 toxicity. (F) Data-mining of the DepMap database reveals that protein expression of the top hits identified in the CRISPR/Cas9-mediated loss-of-function screen inversely correlate with MYC but not ATM expression in human DLBCL. (A,C,E) Cytotoxicity experiments were conducted on ≥5 separate occasions and data presented as mean ± SEM. Statistical significance versus Vehicle (*), MMF (†), AZD1775 (+), or MMF + MYCi (‡), was ascertained by matched multi-comparison (A) one-way or (C,E) two-way ANOVA with Tukey post-hoc test denoted by: *P≤0.05, **P≤0.01, ***P≤0.005, ****P≤0.001, *****P≤0.0005.

Figure 8. Nucleotide depletion induces replication stress-mediated apoptosis in human DLBCL cells with high MYC expression. (A-E) Exposure (72h) of OCI-LY3; a representative human DLBCL cell line with high MYC expression; to vehicle, MMF (1000nM) or AZD1775 (200nM), alone or in combination, led to (A,B) cell death primarily via apoptosis as ascertained by (A) DAPI staining (n=4) and confirmed by (B) AxV/PI status (n=4): viable (AxV-/PI-), early apoptotic (AxV+/PI-), late apoptotic (AxV+/PI+), and secondary necrotic (AxV-/PI+). (C) Cell cycle profiles showed an accumulation of cells in S-phase upon all treatments (n=4). (D) MMF (1000nM) treatment alone and in combination with AZD1775 (200nM) led to accumulation of non-replicating (inactive, EDU-) cells residing in S-phase (n=4). (E) Replication stress response generated by either AZD1775 or MMF treatment is evident in the high MYC-expressing OCI-LY3 DLBCL cell line. Irradiated (IR, 6Gy, 30min) CII-ATM KD CLL cell line and A-T patient-derived LCLs serve as positive controls. Band intensities quantified using Image J were normalized to VINCULIN from ≥3 western blots. (F) Schematic summarizing the mechanistic basis of targeting nucleotide biosynthesis in MYC-overexpressing DLBCL. (A-E) Experiments were conducted on ≥3 separate occasions and data presented as mean ± SEM. Statistical significance versus Vehicle (red), MMF (orange), AZD1775 (blue), Viable (*), Early Apoptotic (†), Late Apoptotic or Inactive (+), or Necrotic (‡), was ascertained by matched multi-comparison (A) one-way or (B-D) two-way ANOVA with Tukey post-hoc test denoted by: *P≤0.05, **P≤0.01, ***P≤0.005, ****P≤0.001, *****P≤0.0005, ******P≤0.0001.
Figure 1

A. Atm^{−/−} X Nu^{−/−}
- Thymoma
- T lymphopenia
- Atm^{−/−}Nu^{−/−}
- B-cell lymphoma
- Genome-scale analysis
- RNA-seq
- CRISPR screen
- Cellular dependencies
- Validation in human DLBCL cell lines

B. % Overall survival vs. Week
- Green: Atm^{−/−}
- Blue: Atm^{−/−}nu^{+/−}
- Purple: Atm^{+/+}nu^{−/−}
- Red: Atm^{−/−}nu^{−/−}
- 7-69 weeks:

C. Immunohistochemistry images:
- CD10
- CD3
- CD20
- Ki67
- 5F1
- CD10
- CD3
- B220
- PAX5
- IRF4
- FOXP1
- 519
Figure 8

A

% Apoptotic of total DAPI+ve cells

Vehicle  MMF  AZD1775  MMF + AZD1775

B

% of Cells

Necrotic  Late Apoptotic  Early Apoptotic  Viable

Vehicle  MMF  AZD1775  MMF + AZD1775

C

% of Viable cells

Vehicle  MMF  AZD1775  MMF + AZD1775

G0/G1  S  G2M

Cell cycle phase

D

% of S-phase viable cells

Vehicle  MMF  AZD1775  MMF + AZD1775

E

pCHK1/CHK1 normalized protein expression

Vehicle  MMF  AZD1775  IR

CIL-ATM KD  A-T hLCLs  OCI-LY3 hDLBCL

F

Initiating event (ATM loss)

RRM2  High MYC expression

Nucleotide synthesis  Proliferation  Cell survival

AZD1775 (WEE1)

MMF

Initiating event (ATM loss)

RRM2  High MYC expression

Nucleotide synthesis  Proliferation  Apoptosis

AZD1775 (WEE1)
Supplementary Material

Supplementary Methods

Genotyping of Atm−nu− mice

Atm genotype was confirmed by PCR, utilizing primer pairs that recognize a consensus Atm sequence.1

Cell lines

Human DLBCL cell lines were obtained from DSMZ (Braunschweig, Germany; BJAB, HT, OCI-LY1, OCI-LY3, RC-K8, SUDHL5, U2932, WILL-2), ATCC (Manassas, VA; Farage, HBL1) or ECACC (Porton Down, UK; KARPAS-422). Human Burkitt lymphoma cell lines were obtained from DSMZ (BJAB, DG75). Lymphoblastoid cell lines (LCL) were previously generated.2 The CII-ATM/GFP CLL cell lines were previously generated from CII (obtained from Prof. A Rosen, Linkoping University, Sweden).2 All human cell lines were cultured in RPMI containing 10% FCS and 1% penicillin/streptomycin.

Murine Eμ–Myc cell lines; modelling Burkitt lymphoma; were established from Eμ-Myc transgenic lymphomas.3

Cytotoxicity assays

Cell lines were treated with MMF, AZD1775, pevonedistat (MLN4924; Selleckchem), MYC inhibitor (MYCi361; Selleckchem) and nucleosides (Sigma-Aldrich, Poole, UK) either alone or in combination. Cytotoxicity was determined by alamar blue uptake (Sigma-Aldrich), CellTiter-Glo (Promega, Southampton, UK), or propidium iodide (PI; Sigma-Aldrich) exclusion, and analyzed using a PHERAstar (BMG Labtech, Aylesbury, UK) or Enspire (PerkinElmer, Beaconsfield, UK) microplate reader or LSRFortessa™ X-20 Cell Analyzer (BD Biosciences, Oxford, UK). All experiments were performed at least in triplicate. Combination indices (CI) to identify synergism and 50% effective concentration (EC50) were calculated using CalcuSyn (Biosoft, Cambridge, UK).

V(D)J recombination analysis
Sanger sequencing of V(D)J rearrangements was undertaken according to standard protocols. Analysis was carried out using the NCBI Ig Blast software.

**FACS analysis**

Cells were analyzed using a CyAn ADP FACS analyzer (Beckman Coulter, High Wycombe, UK) and Summit software (v4.3). Non-specific antibody binding was blocked by anti-mouse CD16/32 before staining with CD3, CD4-PE, CD8a-APC, CD5-APC, B220-E450, CD43-PE, IgM and IgD antibodies (eBiosciences, Altrincham, UK).

Cell cycle analysis was performed according to standard methods. Apoptosis was determined with an Annexin V (AxV) Apoptosis Detection kit (eBiosciences). γH2AX expression was determined using γH2AX-FITC antibody (Millipore, Watford, UK) and the Click-iT™ EdU Alexa Fluor™ 647 Flow Cytometry Assay Kit (ThermoFisher, Gloucester, UK). All analysed using the BD LSFRFortessa™ X-20 and FlowJo v10.8.0.

**Immunohistochemistry**

Immunohistochemistry was performed using antibodies against B220 (BD Biosciences), CD20 (Life Technologies), CD21 (Abcam, Cambridge, UK), CD10 (Bioss, Boston, MA), CD3, IRF4 (Dako, Cambridge, UK; Abcam), BCL2 (Novus, Abingdon, UK), Ki67, PAX5 (BD Biosciences), and FOXP1 (AbD Serotec, Watford, UK).

**RNA-seq analysis**

RNA was isolated from Atm−/−nu−/− lymphomas and Atm+/−nu−/− or Atm+/nu−/− splenic B-cells using the RNeasy Micro Kit (Qiagen, Manchester, UK), quantified using Qubit, and quality assessed using TapeStation (Agilent, Manchester, UK). RNA-seq libraries generated using Neoprep mRNA kits (Illumina, Cambridge, UK) were sequenced on the NextSeq 500 platform (Illumina). For comparison, RNA-seq data of human DLBCL from the Cancer Genome Characterization Initiative (CGCI) study was downloaded from dbGap (http://www.ncbi.nlm.nih.gov/gap; accession phs000532). RNA-seq data for the control germinal center (GC) B-cell samples were obtained from the Gene Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/; accession GSE45982).
Murine and human transcriptome data were aligned to GRCm38.p5 and hg19 respectively using Rsubread aligner, and assigned to individual genes using the Counts function (data available upon request). The edgeR package in R was used to normalize read counts between samples, convert to counts-per-million (CPM) reads for each gene and analyze differential expression between sample groups. Genes were considered to be differentially expressed if fold-change >2 and Benjamini-Hochberg adjusted P<0.05. Differential expression heatmaps were constructed using the gplots and ComplexHeatmap library in R. CPM values for each relevant gene were centered at zero, scaled separately and capped at +/- 3 before applying the Euclidean distance measure in conjunction with the Ward.D2 clustering algorithm. Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway analysis and Gene Set Enrichment Analysis (GSEA v3.0) were executed using clusterProfiler package in R.

**Fluorescence in situ hybridization (FISH)**

Metaphases (≤40) were analyzed using the ISIS software (Didcot, UK) and images captured using a Zeiss Axio imager (Birmingham, UK). The murine chromoprobe multiprobe octochrome system was used for M-FISH (Cytocell, Bicester, UK). Targeted-FISH probes were custom made from the following BAC: IgH alpha-5-ROX dUTP (RP23-455J10), IgH V1 5-Fluorescein dUTP (RP23-303N6) and c-Myc 5-ROX dUTP (RP23-307D14) (Empire Genomics, Buffalo, NY). Circos plots of chromosomal translocations were created using the Rcircos library in R.

**Western Blotting**

Western blotting was performed using ATM (Sigma-Aldrich; Abcam), phospho (p)-ATM (Millipore), NBS1, p-NBS1 (Abcam), SMC1 (Bethyl, Montgomery, Texas, USA), MYC, RRM2, ATR, CHK1 (Santa Cruz, Wembley, UK), p-CHK1 (Cell Signaling, Leiden, Netherlands) VINCULIN or ACTIN (Sigma-Aldrich) primary antibodies and HRP-conjugated anti-rabbit or anti-mouse secondary antibodies (Dako). Immunoreactive bands were visualized using ECL solution and X-Ray film (GE Healthcare Life Sciences, Amersham, UK).

**Immunocytochemistry**

Cell death was evaluated using 4’,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich) counterstaining, goat anti–Lamin B (Atlas Antibodies, Stockholm, Sweden) and rabbit anti-p-
Histone H3 serine-10 (Cell Signaling) primary antibodies and anti-mouse (Alexa Fluor™ 594) and anti-rabbit (Alexa Fluor™ 488; Life Technologies) secondary antibodies. At least 100 cells were analyzed using a Nikon Eclipse E600 (Surbiton, Surrey).

**DNA Fiber analysis**

DNA fiber analysis was performed according to established protocols using idodeoxyuridine (IdU; Sigma-Aldrich), chlorodeoxyuridine (cldU; Sigma-Aldrich), rat- and mouse-bromodeoxyuridine (BrdU) antibodies (Abcam; BD Biosciences). DNA fibers were analyzed using ImageJ.
Supplementary Figures

Figure S1. *Atm*<sup>−/−</sup>*nu*<sup>−/−</sup> mice that develop lymphoma have prolonged overall survival irrespective of the cause of death

Kaplan-Meier curves displaying equivalent overall survival of *Atm*<sup>−/−</sup>*nu*<sup>−/−</sup> mice that have died due to lymphoma or other causes including infection (*P*≤0.05).
Figure S2. *Atm*<sup>−/−</sup> *nu*<sup>−/−</sup> mice develop B-cell lymphomas with complex karyotype that closely model human activated B-cell-like (ABC) and germinal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL).

A

B

Human: Healthy B-cells, ABC-type, GCB-type, Other/U
Mouse: *Atm*<sup>−/−</sup> *nu*<sup>−/−</sup> splenic B-cells, *Atm*<sup>−/−</sup> *nu*<sup>−/−</sup> lymphoma

ABC genes

GCB genes
Characterization of the tumors derived from the Atm<sup>−/−</sup>nu<sup>−/−</sup> murine model. (A) Identification of cellular phenotype by FACS analysis of three cell lines established from Atm<sup>−/−</sup>nu<sup>−/−</sup> lymphomas (5F3, 50F2 and 703). Top: Representative FACS plots (703). Bottom: Cells compromising the murine DLBCL cell lines were classified as ABC (blue), GCB (orange) or other (grey) by sequential gating of subpopulations according to the Hans algorithm (https://www.leukaemia.org.nz/content/uploads/2019/11/DLBCL-LNZ-Protocol-2019.pdf) modified with the addition of BCL2 to differentiate non-GCB into ABC (BCL2<sup>+</sup>) and other (BCL2<sup>−</sup>) subtypes. The minimum percentage of cells expressing the marker to be considered positive for by immunohistochemistry is shown in the left hand diagram. Corresponding FACS analysis indicates that 50F2 and 703 cell lines are ABC DLBCL and 5F3 is other DLBCL. The outcome was confirmed upon replacement of MUM1 with FOXP1. (B) Comparison of
ribonucleic acid (RNA)-seq data of \textit{Atm}^{-}\textit{nu}^{-} lymphomas (n=11) and control splenic B-cells from \textit{Atm}^{+/}\textit{nu}^{+} and \textit{Atm}^{-}/\textit{nu}^{-} mice (n=2) against published RNA-seq datasets of human ABC DLBCL and healthy control germinal center (GC) B-cells\textsuperscript{7,8} suggests that the majority of \textit{Atm}^{-}\textit{nu}^{-} lymphomas cluster with human ABC DLBCL.\textsuperscript{17} (C) Specific translocations involving \textit{IgH} and \textit{MYC}, that are known drivers of \textit{MYC} overexpression in human DLBCL, were specifically probed for by targeted-FISH whilst multiple cytogenetic alterations were detected by M-FISH in six representative \textit{Atm}^{-}\textit{nu}^{-} DLBCL. A normal metaphase spread should depict two copies of each targeted gene, with co-localization of the two \textit{IgH} probes, as indicated by the arrows (703, 37M3, 50F2; \textit{IgHa}, red; \textit{IgHVi}, green; \textit{Myc}, red). Differing copy numbers indicate gains and losses of the relevant gene (5F3, 593, 68F2). Translocations of the \textit{IgH} locus were evidenced by non-co-localized staining of the \textit{IgHa} and \textit{IgHVi} probes, upon evidence of which, spreads were assessed for co-localization of \textit{Myc} and \textit{IgHVi} probes to identify whether \textit{IgH-Myc} fusion had occurred (68F2). Whilst there was no evidence that \textit{Atm}^{-}\textit{nu}^{-} DLBCL harbored the human DLBCL \textit{IgH-MYC} fusion, other abnormalities were detected: \textit{Myc} gain (5F3, 68F2), \textit{IgH} loss (5F3, 593), \textit{IgH} translocation (68F2). The Circos plots depict the chromosomal interactions derived from identified aberrations for individual tumors and all 6 representative \textit{Atm}^{-}\textit{nu}^{-} B-cell lymphoma combined. Chromosomes are indicated by the numerals and annotated with lymphoma relevant genes localized in the regions affected by chromosomal alterations. No common translocation was observed.
Figure S3. Myc and Myc target gene expression is upregulated in Atm−/−nu−/− lymphomas.
(A) Alignment of the transcriptional profiles of $Atm^{−/−}nu^{−/−}$ lymphomas (n=12) and control splenic B-cells from $Atm^{−/−}nu^{−/−}$ and $Atm^{−/−}nu^{−/−}$ mice (n=2), human ABC DLBCL$^7$ (n=32), GCB DLBCL$^7$ (n=54), other/unknown (U) DLBCL (n=18) and healthy control GC B-cells$^8$ (n=4) according to the expression of MYC target genes.$^{18}$ This reveals that a high proportion of $Atm^{−/−}nu^{−/−}$ DLBCL (red) align with a high (subset 3) MYC target gene-expressing group, whereas the $Atm^{−/−}nu^{−/−}$ and $Atm^{−/−}nu^{−/−}$ controls (black) align with the low (subset 2) MYC target gene-expressing group. (B) Compared to controls, RNA-seq analysis of $Atm^{−/−}nu^{−/−}$ lymphomas (n=11) suggests differential upregulation of MYC but not other lymphoma relevant genes. (C) In comparison to human ATM WT and deficient tumor (CLL CII-cell line) and non-tumor (three healthy and A-T patient-derived LCL) controls, MYC protein expression is upregulated in two cell lines established from $Atm^{−/−}nu^{−/−}$ lymphomas (5F3 and 50F2) and some human DLBCL cell lines (OCI-LY3 and WILL-2). Band intensities quantified using Image J were normalized to VINCULIN from ≥3 western blots and presented as mean ± SEM.
Figure S4. Cellular dependency pathways of Atm<sup>−/−</sup> nu<sup>−/−</sup> lymphomas identified by a genome-wide CRISPR/Cas9 screen
Identification of potential therapeutic targets for $Atm^{+/}\text{nul}^{-}$ lymphomas by genome-scale CRISPR/Cas9-mediated loss-of-function screen of two cell lines established from $Atm^{+/}\text{nul}^{-}$ lymphomas (50F2 and AN017) with an FDR <0.05. Constituent genes of each of the most significantly affected biological processes identified by RNA-seq, were depleted in both lymphoma cell lines and present potential therapeutic targets.
Figure S5. Nucleotide depletion induces cytotoxicity in $E_{\mu}$-Myc lymphoma and replication stress in MYC-dependent $Atm^{--}nu^{--}$ lymphomas

A

B
(A) Exposure (72h) of 3 Atm wild-type, E\(\mu\)-Myc-driven lymphoma cell lines to inhibitors of nucleotide synthesis (MMF or AZD1775; n=3) indicates sensitivity to both treatments as measured by Annexin V FACS analysis. Data presented as mean ± SEM. Statistical significance versus untreated controls (*), was ascertained by repeat-measures matched multi-comparison one-way ANOVA with Tukey post-hoc test and denoted by: *\(P\leq0.05\), **\(P\leq0.01\), ***\(P\leq0.001\), ****\(P\leq0.0005\), *****\(P\leq0.00005\). (B) In comparison to human ATM-deficient non-tumor (three A-T patient-derived LCL) controls, basal RRM2 protein expression and a replicative stress indicator (phosphorylated CHK1 to total CHK1 protein ratio) are lower in a representative cell line established from an Atm\(^{-}\)nu\(^{-}\) lymphoma (50F2) whilst ATR is elevated. IR-induced (6Gy, 30min) replication stress in the A-T patient-derived LCL resulted in reduced RRM2 expression and concurrent elevated CHK1 phosphorylation which was replicated upon AZD1775 (500nM) but not MMF (250nM) treatment (72h) of an Atm\(^{-}\)nu\(^{-}\) lymphoma (50F2). Band intensities quantified using Image J were normalized to VINCULIN from ≥3 western blots and presented as mean ± SEM. (C) The proportion of \(\gamma\)H2AX\(^{+}\) cells in non-replicating (inactive, quiescent) S-phase was determined by flow cytometry. Cell cycle stage was identified by DAPI staining and replicating cells by EDU. The dot plot illustrates the gating strategy employed to select non-replicating (EDU\(^{-}\)) cells residing in S-phase in a representative vehicle-treated sample. The \(\gamma\)H2AX expression of EDU\(^{-}\) S-phase cells treated with vehicle (red), MMF (orange), AZD1775 (blue) or MMF + AZD1775 combined (green) cells on the right clearly demonstrates the accumulation of \(\gamma\)H2AX in non-replicating S-phase cells (EDU\(^{-}\) \(\gamma\)H2AX\(^{+}\)) following combination treatment.
Figure S6. Elevated MYC expression sensitizes human DLBCL cells to nucleotide depletion

A

B

C

D

15
(A,B) Exposure (72h) of 11 human DLBCL cell lines with varying degrees of MYC expression to inhibitors of nucleotide synthesis (MMF or AZD1775; n=5) indicated a trend between MYC expression and increased cytotoxicity as measured by CellTitre-Glo for WEE1 inhibition (AZD1775). (C,D,E) Sensitivity to nucleotide synthesis inhibition is ATM-independent as evidenced by lack of differential sensitivity in (C) LCL cells derived from three healthy volunteers (WT LCL) versus three A-T patients (AT LCL) and (D) shRNA-ATM-KD CII cells (CLL tumor cell lines) and also (A,E) non-responsiveness of the sole cell line exhibiting loss of functional ATM (Farage); assessed by lack of multiple parameters of functional activity following irradiation (IR, 5 Gy, 30 min) of the cell lines. Samples were run on two separate gels. (F) Comparison of human DLBCL subsets and germinal centers by data-mining published human DLBCL RNA-seq datasets of human ABC DLBCL (n=32), GCB DLBCL (n=54), U DLBCL (n=10), Other DLBCL (n=8) and healthy control GC B-cells (n=4). In comparison to GC B-cells, patient ABC DLBCL expresses significantly reduced ATM whilst expression of both MYC and a purine/pyrimidine biosynthesis gene-set is higher in ABC-DLBCL than GC B-cells and GCB DLBCL. ABC, activated B-cell-like; GCB, germinal center.
B-cell-like; U, unknown; Other, other; GC, germinal center B-cells. Statistical significance versus (A) untreated controls (*), AZD1775 (†) or MMF (†) concentration as denoted by symbol color, (C,D) untreated controls (*) or WT or GFP KD (†) as denoted by color, was ascertained by repeat-measures matched multi-comparison two-way ANOVA with Tukey post-hoc test and denoted by: *P≤0.05, **P≤0.01, ***P≤0.005, ****P≤0.001, *****P≤0.0005.
Figure S7. Human Burkitt lymphoma cells exhibiting high MYC expression are sensitive to nucleotide depletion

Exposure (72h) of human Burkitt lymphoma cell lines to inhibitors of nucleotide synthesis (MMF or AZD1775; n=5) indicates sensitivity to combined AZD/MMF treatment in BJAB (high MYC) but not DG75 (low MYC) (Figure S6E).\textsuperscript{19} Statistical significance versus untreated controls (*), AZD1775 (+) or MMF (†) concentration as denoted by symbol color, was ascertained by repeat-measures matched multi-comparison two-way ANOVA with Tukey post-hoc test and denoted by: *$P \leq 0.05$, **$P \leq 0.01$, ***$P \leq 0.005$, ****$P \leq 0.001$, *****$P \leq 0.0005$. 
References


Supplementary Tables provided as Excel files except Table 2.

Table S1. Classification features of \( \text{Atm}^{+} \text{nu}^{+} \) tumors

Microsoft Excel Table S1

Note: DLBCL, NOS, diffuse large B-cell lymphoma, not otherwise specified; +, present; ND, not done; -, not present; NA, not amplified; ~, undetermined; M, mutated; UM, unmutated.
Table S2. Cytogenetic profiles of Atm<sup>−/−</sup> nu<sup>−/−</sup> diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) tumors

<table>
<thead>
<tr>
<th>Tumor code</th>
<th>M-FISH</th>
<th>Number of analysed cells</th>
<th>Myc copy number</th>
<th>IgH translocation</th>
<th>IgH loss</th>
</tr>
</thead>
<tbody>
<tr>
<td>703</td>
<td>36~41, XX, der(X)t(X;13)[11], der(13)t(13;18)[9], der(18)t(18;X)[8], +6[4], -X[8], -4[4], -3[3], -5[5], -13[3], -15[3], -16[4], -17[4], -18[4], -19[3], add(6)[4], der(X)t(X;6)[3]</td>
<td>36</td>
<td>2</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>5F3</td>
<td>39~40, XX, der(17)t(11;17)[19], -11[17], -16[15], add(6)[15], dup(14)[5], der(18)t(15;12;18)<em>[8], der(18)t(15;18)</em>[8], der(6)t(1;6), der(1)t(1;16)[3]</td>
<td>20</td>
<td>3</td>
<td>No</td>
<td>Monoallelic IgH V1</td>
</tr>
<tr>
<td>593</td>
<td>39~40, XY, der(17)t(15;17)[19], -Y[6], -11[3], dup(4)[6], add(4)[6], der(13)t(3;13)[7], der(5)t(5;4)[4]</td>
<td>20</td>
<td>2</td>
<td>No</td>
<td>IgH</td>
</tr>
<tr>
<td>37M3</td>
<td>30~40, XY, der(18)t(12;18)[6], der(18)t(8;18)[4], der(18)t(5;18)[3], der(18)t(7;18)[3], -12[5], dup(18)[4], add(1)[3], add(3)[3], add(5)[3], add(11)[3], t(1;2)[5]</td>
<td>40</td>
<td>2</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>50F2</td>
<td>30~41, XX, dup(18)der(18)t(7;18)[12], -19[5], -5[4], -7[4], -8[4], -9[4], -2[3], -12[3], -16[3]</td>
<td>20</td>
<td>2</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>68F2</td>
<td>40, XX (Normal)[4]/40~41, XX, der(12)t(12;15)[8], -19[5], +3[5], +12[5], der(19)t(12;19)[3]</td>
<td>12</td>
<td>3</td>
<td>Yes</td>
<td>No</td>
</tr>
</tbody>
</table>

Note: FISH, fluorescence in-situ hybridization; M-FISH, multicolor-FISH; [#], denotes the number of cells in which the abnormality was detected; *, Due to technical limitations of M-FISH analysis these aberrations have been denoted separately but could potentially be the same.
Table S3. RNA-seq: Significantly differentially expressed genes

Microsoft Excel Table S3

Note: baseMean, mean of normalized counts of all samples; log2FoldChange, effect size estimate of the expression change between comparison and control groups; lfcSE, standard error of the log2FoldChange; stat, Wald-log test statistic; pvalue, raw p-value; padj, false discovery rate p-value; 1-593.bam; Atm⁻/⁻nu⁻ lymphoma sample (593 replicate 1) bam files; plus.minus.bam, control Atm⁺/⁺nu⁻ splenic B-cell bam file; plus.plus.bam, control Atm⁺/⁺nu⁻ splenic B-cell bam file.

Table S4. RNA-seq Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway analysis: Upregulated gene expression pathways

Microsoft Excel Table S4

Note: ID, unique identifier for each KEGG object; GeneRatio, fraction of differentially expressed genes found in the gene set; BgRatio, fraction of differentially expressed genes annotated to a pathway; p.adjust, corrected p-value using false discovery rate methods; qvalue, p-value using multiple hypothesis test correction indicates the probability that a reaction module was identified by chance; geneID, EntrezGene ID; Count, number of genes enriched in a KEGG pathway; Log_pvalue, log₁₀ of the p-value; Log_qvalue, log₁₀ of the q-value; Log_padjust, log₁₀ of the p.adjust-value.

Table S5. RNA-seq Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathway analysis: Downregulated gene expression pathways

Microsoft Excel Table S5

Note: ID, unique identifier for each KEGG object; GeneRatio, fraction of differentially expressed genes found in the gene set; BgRatio, fraction of differentially expressed genes
annotated to a pathway; p.adjust, corrected p-value using false discovery rate methods; qvalue, p-value using multiple hypothesis test correction indicates the probability that a reaction module was identified by chance; geneID, EntrezGene ID; Count, number of genes enriched in a KEGG pathway; Log_pvalue, log_{10} of the p-value; Log_qvalue, log_{10} of the q-value; Log_padjust, log_{10} of the p.adjust-value.

Table S6. RNA-seq Gene Set Enrichment Analysis (GSEA): Upregulated hallmarks

Microsoft Excel Table S6

Note: pval, nominal p value, the statistical significance of the enrichment score that is of limited use in comparing gene sets; padj, false discovery rate p-value; ES, enrichment score for the gene set, the degree to which this gene set is overrepresented at the top or bottom of the ranked list of genes in the expression dataset; NES, normalized enrichment score for the gene set; nMoreExtreme, number of times a control gene set had a more extreme enrichment score value, used to calculate nominal p-value; Size, number of genes present in the expression dataset; leadingEdge, subset of genes that contribute most to the ES.

Table S7. Clustered regularly interspaced short palindromic repeats (CRISPR): Comparison of sgRNA target gene expression at Day 18 vs Day 0 in two A-T DLBCL derived cell-lines

Microsoft Excel Table S7

Note: Score, MAGeCK Robust Rank Aggregation (RRA) enrichment score indicates the essentiality of a gene to identify 'hits'; FDR, false discovery rate.

Table S8. Clustered regularly interspaced short palindromic repeats (CRISPR) KEGG pathway analysis: Depleted gene (Hit) expression pathways
Microsoft Excel Table S8

ID, unique identifier for each Kyoto Encyclopaedia of Genes and Genomes (KEGG) object; Observed gene Count, number of identified depleted genes in the KEGG pathway; Background gene Count, number of total genes in the KEGG pathway; FDR, false discovery rate; geneID, EntrezGene ID.